COMPANY RESEARCHHBM Holdings Ltd.
Harbour BioMed, also known through its listed entity HBM Holdings, is a Hong Kong-listed biopharmaceutical company developing antibody-based therapeutics. Its technology platforms include the discovery of fully human antibodies, heavy-chain-only antibodies and additional engineered antibody formats. Oncology and immunology are important therapeutic areas. The company combines proprietary discovery activities with research partnerships and licensing arrangements. Its official website describes its antibody platform and identifies the Hong Kong listing. These antibody engineering capabilities support its oncology and immunology research strategy.
Company at a glance
Corporate information
- Company entity
- HBM Holdings Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.harbourbiomed.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
HKEX: 02142
fully human antibodies · heavy-chain-only antibodies · bispecific immune-cell engagers
oncology · immunology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Harbour BioMed, also known through its listed entity HBM Holdings, is a Hong Kong-listed biopharmaceutical company developing antibody-based therapeutics. Its technology platforms include the discovery of fully human antibodies, heavy-chain-only antibodies and additional engineered antibody formats. Oncology and immunology are important therapeutic areas. The company combines proprietary discovery activities with research partnerships and licensing arrangements. Its official website describes its antibody platform and identifies the Hong Kong listing. These antibody engineering capabilities support its oncology and immunology research strategy.
Business, technology & evidence
- SecuritiesHKEX: 02142
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · HBM Holdings Ltd. ↗HBM Holdings Ltd. ·
- Official issuer and R&D disclosure · HBM Holdings Ltd. ↗HBM Holdings Ltd. ·
- Official issuer and R&D disclosure · HBM Holdings Ltd. ↗HBM Holdings Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.